Arq Bras Endocrinol Metab 2000;44(2):121-124
Metformin and The United Kingdom Prospective Diabetes Study: A Commentary
DOI: 10.1590/S0004-27302000000200003
DOI: 10.1590/S0004-27302000000200003
Flow diagram of patient exclusion criteria for SNMTC and FNMTC groups.
Campbell IW. Metformin and The United Kingdom Prospective Diabetes Study: A Commentary. Arq Bras Endocrinol Metab 2000;44(2):121-4.
Campbell, Ian W.. Metformin and The United Kingdom Prospective Diabetes Study: A Commentary. Arq Bras Endocrinol Metab, v. 44, n. 2, p. 121-124, Apr. 2000.
Campbell, I. W. (2000). Metformin and The United Kingdom Prospective Diabetes Study: A Commentary. Arq Bras Endocrinol Metab, 44(2), 121-124.
Campbell, Ian W.. Metformin and The United Kingdom Prospective Diabetes Study: A Commentary. Arq Bras Endocrinol Metab [online]. 2000, vol. 44, n. 2, [cited 2026-03-08], pp.121-124. Available from: <https://www.aem-sbem.com/article/metformin-and-the-united-kingdom-prospective-diabetes-study-a-commentary/>. ISSN 2359-3997.